Skip to main content Accessibility help
×
Home
  • Online publication date: March 2015

Chapter 36 - The uterine cervix

References

1. Fu YS, Reagan JW. Pathology of the Uterine Cervix, Vagina and Vulva. Philadelphia, PA: WB Saunders; 1989.
2. Gustafson R. The vascular lymphatic and neural anatomy of the cervix. In: Jordon JAS, ed. The Cervix. London: WB Saunders; 1976.
3. Fluhman C. The Cervix Uteri and Its Diseases. Philadelphia, PA: WB Saunders; 1961.
4. Madile BM. The cervical epithelium from fetal age to adolescence. Obstet Gynecol 1976; 47: 536–539.
5. Pixley E. Basic morphology of the prepuberal and youthful cervix: topographic and histologic features. J Reprod Med 1976; 16: 221–230.
6. Clement PB. Multinucleated stromal giant cells of the uterine cervix. Arch Pathol Lab Med 1985; 109: 200–202.
7. Maguire NC. Current use of the Papanicolaou class system in gynecologic cytology. Diagn Cytopathol 1988; 4: 169–176.
8. Koss LG. The new Bethesda System for reporting results of smears of the uterine cervix. J Natl Cancer Inst 1990; 82: 988–991.
9. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–2119.
10. Solomon D. The Bethesda System for reporting cervical/vaginal cytologic diagnosis: an overview. Int J Gynecol Pathol 1991; 10: 323–325.
11. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. Definitions, Criteria and Explanatory Notes for Terminology and Specimen Adequacy. New York, NY: Springer-Verlag; 1994.
12. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120–2129.
13. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346–355.
14. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012; 16: 205–242.
15. Ransdell JS, Davey DD, Zaleski S. Clinicopathologic correlation of the unsatisfactory Papanicolaou smear. Cancer 1997; 81: 139–143.
16. Hutchinson ML, Isenstein LM, Goodman A, et al. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor. Am J Clin Pathol 1994; 101: 215–219.
17. Moore D, Pugh-Cain D, Walker T. Cervical smear adequacy: cellularity references were found to increase both interobserver agreement and unsatisfactory rate. Cytopathology 2009; 20: 161–168.
18. Cox JT. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice. J Natl Compr Canc Netw 2004; 2: 597–611.
19. Hoda RS, Loukeris K, Abdul-Karim FW. Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences. Diagn Cytopathol 2012; 41: 257–278.
20. Haroon S, Samayoa L, Witzke D, Davey D. Reproducibility of cervicovaginal ThinPrep cellularity assessment. Diagn Cytopathol 2002; 26: 19–21.
21. Studeman KD, Ioffe OB, Puszkiewicz J, Sauvegeot J, Henry MR. Effect of cellularity on the sensitivity of detecting squamous lesions in liquid-based cervical cytology. Acta Cytol 2003; 47: 605–610.
22. Birdsong GG. Pap smear adequacy: is our understanding satisfactory . . . or limited? Diagn Cytopathol 2001; 24: 79–81.
23. Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999; 354: 1763–1770.
24. Vooijs PG, Elias A, van der Graaf Y, Veling S. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 1985; 29: 323–328.
25. Mintzer M, Curtis P, Resnick JC, Morrell D. The effect of the quality of Papanicolaou smears on the detection of cytologic abnormalities. Cancer 1999; 87: 113–117.
26. Bos AB, van Ballegooijen M, Elske van den Akker-van Marle M, et al. Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 2001; 115: 851–855.
27. Mitchell HS. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. Cancer 2001; 93: 237–240.
28. Davey DD, Cox JT, Austin RM, et al. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis 2008; 12: 71–81.
29. Rosa M, Pragasam P, Saremian J, et al. The unsatisfactory ThinPrep(R) Pap Test: analysis of technical aspects, most common causes, and recommendations for improvement. Diagn Cytopathol 2013; 41: 588–594.
30. Fontaine D, Narine N, Naugler C. Unsatisfactory rates vary between cervical cytology samples prepared using ThinPrep and SurePath platforms: a review and meta-analysis. BMJ Open 2012; 2: e000847.
31. Sweeney BJ, Haq Z, Happel JF, Weinstein B, Schneider D. Comparison of the effectiveness of two liquid-based Papanicolaou systems in the handling of adverse limiting factors, such as excessive blood. Cancer 2006; 108: 27–31.
32. Dalton P, MacDonald S, Boerner S. Acetic acid recovery of gynecologic liquid-based samples of apparent low squamous cellularity. Acta Cytol 2006; 50: 136–140.
33. Davey DD, Woodhouse S, Styer P, Stastny J, Mody D. Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 2000; 124: 203–211.
34. Birdsong GG, Darraugh DD, Elgert TM, Henry PA. MR specimen adequacy. In: Solomon D, Najur R, eds., The Bethesda System for Reporting Cervical Cytology, 2nd edn. New York, NY: Springer; 2004.
35. Hein M, Valore EV, Helmig RB, Uldbjerg N, Ganz T. Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol 2002; 187: 137–144.
36. Critchlow CW, Wolner-Hanssen P, Eschenbach DA, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol 1995; 173: 534–543.
37. Young RH, Harris NL, Scully RE. Lymphoma-like lesions of the lower female genital tract: a report of 16 cases. Int J Gynecol Pathol 1985; 4: 289–299.
38. Ramalingam P, Zoroquiain P, Valbuena JR, Kemp BL, Medeiros LJ. Florid reactive lymphoid hyperplasia (lymphoma-like lesion) of the uterine cervix. Ann Diagn Pathol 2012; 16: 21–28.
39. Geyer JT, Ferry JA, Harris NL, et al. Florid reactive lymphoid hyperplasia of the lower female genital tract (lymphoma-like lesion): a benign condition that frequently harbors clonal immunoglobulin heavy chain gene rearrangements. Am J Surg Pathol 2010; 34: 161–168.
40. Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193: 617–624.
41. O’Duffy JD, Carney JA, Deodhar S. Behcet’s disease. Report of 10 cases, 3 with new manifestations. Ann Intern Med 1971; 75: 561–570.
42. Darwin LH, Cullen AP, Arthur PM, et al. Comparison of Digene hybrid capture 2 and conventional culture for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens. J Clin Microbiol 2002; 40: 641–644.
43. Van Dyck E, Ieven M, Pattyn S, Van Damme L, Laga M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol 2001; 39: 1751–1756.
44. Aaltone R, Jalava J, Laurikainen E, Karkkainen U, Alanen A. Cervical ureaplasma urealyticum colonization: comparison of PCR and culture for its detection and association with preterm birth. Scand J Infect Dis 2002; 34: 35–40.
45. Rodrigues MM, Fernandes PA, Haddad JP, et al. Frequency of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis and Ureaplasma species in cervical samples. J Obstet Gynaecol 2011; 31: 237–241.
46. Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002; 101: 371–374.
47. Tamim H, Finan RR, Sharida HE, Rashid M, Almawi WY. Cervicovaginal coinfections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis 2002; 43: 277–281.
48. Safaeian M, Quint K, Schiffman M, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 2010; 102: 1794–1804.
49. Morre SA, Munk C, Persson K, et al. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol 2002; 40: 584–587.
50. Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection. An emerging disease? Infect Dis Clin North Am 1998; 12: 47–61.
51. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992; 326: 1533–1539.
52. Ribes JA, Steele AD, Seabolt JP, Baker DJ. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol 2001; 39: 3321–3325.
53. Lafferty WE. The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 2002; 9: 51–55.
54. Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years–United States, 2005–2008. MMWR Morb Mortal Wkly Rep 2010; 59: 456–459.
55. Corey L, Wald A. Genital herpes simplex virus infections. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases. New York, NY: McGraw-Hill; 1999: pp. 285–312.
56. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983; 98: 973–983.
57. Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clin Microbiol Rev 1995; 8: 549–556.
58. Munoz N, Kato I, Bosch FX, et al. Cervical cancer and herpes simplex virus type 2: case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. Int J Cancer 1995; 60: 438–442.
59. Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997; 53: 4–12.
60. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis 1990; 17: 90–94.
61. Wolff MH, Schmitt J, Rahaus M, Dudda H, Hatzmann W. Clinical and subclinical reactivation of genital herpes virus. Intervirology 2002; 45: 20–23.
62. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002; 78: 21–25.
63. Marshall DS, Linfert DR, Draghi A, McCarter YS, Tsongalis GJ. Identification of herpes simplex virus genital infection: comparison of a multiplex PCR assay and traditional viral isolation techniques. Mod Pathol 2001; 14: 152–156.
64. McGalie CE, McBride HA, McCluggage WG. Cytomegalovirus infection of the cervix: morphological observations in five cases of a possibly under-recognised condition. J Clin Pathol 2004; 57: 691–694.
65. Nankervis GA, Kumar ML, Cox FE, Gold E. A prospective study of maternal cytomegalovirus infection and its effect on the fetus. Am J Obstet Gynecol 1984; 149: 435–440.
66. Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180: 265–269.
67. Bhagavan BS, Ruffier J, Shinn B. Pseudoactinomycotic radiate granules in the lower female genital tract: relationship to the Splendore–Hoeppli phenomenon. Hum Pathol 1982; 13: 898–904.
68. Kaufman RH, Watts JM, Gardner HL. Pemphigus vulgaris: genital involvement. Report of two cases. Obstet Gynecol 1969; 33: 264–266.
69. Agarwal J, Gupta JK. Female genital tuberculosis – a retrospective clinico-pathologic study of 501 cases. Indian J Pathol Microbiol 1993; 36: 389–397.
70. Evans CS, Goldman RL, Klein HZ, Kohout ND. Necrobiotic granulomas of the uterine cervix. A probable postoperative reaction. Am J Surg Pathol 1984; 8: 841–844.
71. Bell DA, Mondschein M, Scully RE. Giant cell arteritis of the female genital tract. A report of three cases. Am J Surg Pathol 1986; 10: 696–701.
72. Viikki M, Pukkala E, Nieminen P, Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol 2000; 39: 71–75.
73. Rand RJ, Lowe JW. Schistosomiasis of the uterine cervix. Br J Obstet Gynaecol 1998; 105: 1329–1331.
74. Gardner HL, Kaufman RH. Benign Diseases of the Vulva and Vagina. Boston, MA: GK Hall; 1981.
75. Suh KS, Silverberg SG. Tubal metaplasia of the uterine cervix. Int J Gynecol Pathol 1990; 9: 122–128.
76. Jonasson JG, Wang HH, Antonioli DA, Ducatman BS. Tubal metaplasia of the uterine cervix: a prevalence study in patients with gynecologic pathologic findings. Int J Gynecol Pathol 1992; 11: 89–95.
77. Oliva E, Clement PB, Young RH. Tubal and tubo-endometrioid metaplasia of the uterine cervix. Unemphasized features that may cause problems in differential diagnosis: a report of 25 cases. Am J Clin Pathol 1995; 103: 618–623.
78. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol 2010; 34: 137–146.
79. Ismail SM. Cone biopsy causes cervical endometriosis and tubo-endometrioid metaplasia. Histopathology 1991; 18: 107–114.
80. Li C, Rock KL, Woda BA, et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007; 20: 242–247.
81. Schlesinger C, Silverberg SG. Endocervical adenocarcinoma in situ of tubal type and its relation to atypical tubal metaplasia. Int J Gynecol Pathol 1999; 18: 1–4.
82. Weir MM, Bell DA, Young RH. Transitional cell metaplasia of the uterine cervix and vagina: an underrecognized lesion that may be confused with high-grade dysplasia. A report of 59 cases. Am J Surg Pathol 1997; 21: 510–517.
83. Egan AJ, Russell P. Transitional (urothelial) cell metaplasia of the uterine cervix: morphological assessment of 31 cases. Int J Gynecol Pathol 1997; 16: 89–98.
84. Duggan MA. Cytologic and histologic diagnosis and significance of controversial squamous lesions of the uterine cervix. Mod Pathol 2000; 13: 252–260.
85. Koss LG. Traditional cell metaplasia of cervix: a misnomer. Am J Surg Pathol 1998; 22: 774–776.
86. Harnden P, Kennedy W, Andrew AC, Southgate J. Immunophenotype of transitional metaplasia of the uterine cervix. Int J Gynecol Pathol 1999; 18: 125–129.
87. Ng WK, Cheung LK, Li AS, Cheung FM, Chow JC. Transitional cell metaplasia of the uterine cervix is related to human papillomavirus: molecular analysis in seven patients with cytohistologic correlation. Cancer 2002; 96: 250–258.
88. Trowell JE. Intestinal metaplasia with argentaffin cells in the uterine cervix. Histopathology 1985; 9: 551–559.
89. Gloor E, Hurlimann J. Cervical intraepithelial glandular neoplasia (adenocarcinoma in situ and glandular dysplasia). A correlative study of 23 cases with histologic grading, histochemical analysis of mucins, and immunohistochemical determination of the affinity for four lectins. Cancer 1986; 58: 1272–1280.
90. Schneider V. Arias-Stella reaction of the endocervix: frequency and location. Acta Cytol 1981; 25: 224–228.
91. Nucci MR, Young RH. Arias-Stella reaction of the endocervix: a report of 18 cases with emphasis on its varied histology and differential diagnosis. Am J Surg Pathol 2004; 28: 608–612.
92. Greeley C, Schroeder S, Silverberg SG. Microglandular hyperplasia of the cervix: a true “pill” lesion? Int J Gynecol Pathol 1995; 14 50–54.
93. Young RH, Scully RE. Atypical forms of microglandular hyperplasia of the cervix simulating carcinoma. A report of five cases and review of the literature. Am J Surg Pathol 1989; 13: 50–56.
94. Young RH, Scully RE. Uterine carcinomas simulating microglandular hyperplasia. A report of six cases. Am J Surg Pathol 1992; 16: 1092–1097.
95. Zaloudek C, Hayashi GM, Ryan IP, Powell CB, Miller TR. Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int J Gynecol Pathol 1997; 16: 52–59.
96. Nucci MR, Clement PB, Young RH. Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. Am J Surg Pathol 1999; 23: 886–891.
97. Mikami Y, Hata S, Melamed J, Fujiwara K, Manabe T. Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype. Histopathology 2001; 39: 364–372.
98. Mikami Y, Minamiguchi S, Teramoto N, et al. Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. Pathol Res Pract 2013; 209: 173–178.
99. Liao SY, Rodgers WH, Kauderer J, et al. Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study. Br J Cancer 2013; 108: 613–620.
100. Mikami Y, Kiyokawa T, Hata S, et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’. Mod Pathol 2004; 17: 962–972.
101. Jones MA, Young RH, Scully RE. Diffuse laminar endocervical glandular hyperplasia. A benign lesion often confused with adenoma malignum (minimal deviation adenocarcinoma). Am J Surg Pathol 1991; 15: 1123–1129.
102. Seidman JD, Tavassoli FA. Mesonephric hyperplasia of the uterine cervix: a clinicopathologic study of 51 cases. Int J Gynecol Pathol 1995; 14: 293–299.
103. McCluggage WG, Oliva E, Herrington CS, McBride H, Young RH. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology 2003; 43: 144–150.
104. Baker PM, Clement PB, Bell DA, Young RH. Superficial endometriosis of the uterine cervix: a report of 20 cases of a process that may be confused with endocervical glandular dysplasia or adenocarcinoma in situ. Int J Gynecol Pathol 1999; 18: 198–205.
105. Clement PB, Granai CO, Young RH, Scully RE. Endometriosis with myxoid change. A case simulating pseudomyxoma peritonei. Am J Surg Pathol 1994; 18: 849–853.
106. Clement PB, Young RH. Deep nabothian cysts of the uterine cervix. A possible source of confusion with minimal-deviation adenocarcinoma (adenoma malignum). Int J Gynecol Pathol 1989; 8: 340–348.
107. Kondo T, Hashi A, Murata SI, et al. Gastric mucin is expressed in a subset of endocervical tunnel clusters: type A tunnel clusters of gastric phenotype. Histopathology 2007; 50: 843–850.
108. Segal GH, Hart WR. Cystic endocervical tunnel clusters. A clinicopathologic study of 29 cases of so-called adenomatous hyperplasia. Am J Surg Pathol 1990; 14: 895–903.
109. Jones MA, Young RH. Endocervical type A (noncystic) tunnel clusters with cytologic atypia. A report of 14 cases. Am J Surg Pathol 1996; 20: 1312–1318.
110. Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol 1999; 30: 687–694.
111. Young RH, Kurman RJ, Scully RE. Placental site nodules and plaques. A clinicopathologic analysis of 20 cases. Am J Surg Pathol 1990; 14: 1001–1009.
112. Kay S, Schneider V. Reactive spindle cell nodule of the endocervix simulating uterine sarcoma. Int J Gynecol Pathol 1985; 4: 255–257.
113. Abenoza P, Shek YH, Perrone T. Inflammatory pseudotumor of the cervix. Int J Gynecol Pathol 1994; 13: 80–86.
114. Nucci MR, Ferry JA, Young RH. Ectopic prostatic tissue in the uterine cervix: a report of four cases and review of ectopic prostatic tissue. Am J Surg Pathol 2000; 24: 1224–1230.
115. Tiltman AJ. Leiomyomas of the uterine cervix: a study of frequency. Int J Gynecol Pathol 1998; 17: 231–234.
116. Gilks CB, Young RH, Clement PB, Hart WR, Scully RE. Adenomyomas of the uterine cervix of endocervical type: a report of ten cases of a benign cervical tumor that may be confused with adenoma malignum [corrected]. Mod Pathol 1996; 9: 220–224.
117. Patel DS, Bhagavan BS. Blue nevus of the uterine cervix. Hum Pathol 1985; 16: 79–86.
118. Uehara T, Takayama S, Takemura T, Kasuga T. Foci of stromal melanocytes (so-called blue naevus) of the uterine cervix in Japanese women. VirchowsArch A Pathol Anat Histopathol 1991; 418: 327–331.
119. Yilmaz AG, Chandler P, Hahm GK, O’Toole RV, Niemann TH. Melanosis of the uterine cervix: a report of two cases and discussion of pigmented cervical lesions. Int J Gynecol Pathol 1999; 18: 73–76.
120. Bonfiglio TA. E. Y. S. Gynecologic Cytopathology. Philadelphia, PA: Lippincott-Raven; 1997.
121. Wilbur DC, Henry MR. College of American Pathologists Practical Guide to Gynecologic Cytopathology. Chicago, IL: CAP Press; 2008.
122. Wilbur DaB, ed. Comprehensive Cytopathology. Philadelphia, PA: Saunders Elsevier; 2008.
123. deMay R, ed. The Art and Science of Cytopathology, 2nd edn. Chicago, IL: ASCP Press; 2011.
124. Patten SF. Diagnostic Cytology of the Uterine Cervix. Baltimore, MD: Williams and Wilkins; 1978.
125. Kaptain S, Bloom LI, Weir MM. Hormonal effects of Depo-Provera in cervical smears: a comparison with Triphasil and postmenopausal effects. Cancer 2002; 96: 74–82.
126. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997; 314: 228–231.
127. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346–355.
128. Heaton RB Jr, Harris TF, Larson DM, Henry MR. Glandular cells derived from direct sampling of the lower uterine segment in patients status post-cervical cone biopsy. A diagnostic dilemma. Am J Clin Pathol 1996; 106: 511–516.
129. Lundeen SJ, Horwitz CA, Larson CJ, Stanley MW. Abnormal cervicovaginal smears due to endometriosis: a continuing problem. Diagn Cytopathol 2002; 26: 35–40.
130. Colgan TJ, Woodhouse SL, Styer PE, Kennedy M, Davey DD. Reparative changes and the false-positive/false-negative Papanicolaou test: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2001; 125: 134–140.
131. Shield PW, Daunter B, Wright RG. Post-irradiation cytology of cervical cancer patients. Cytopathology 1992; 3: 167–182.
132. McLennan MT, McLennan CE. Significance of cervicovaginal cytology after radiation therapy for cervical carcinoma. Am J Obstet Gynecol 1975; 121: 96–100.
133. Pillay B, Gregory AR, Subbiah M. Cytopathologic changes associated with intrauterine contraceptive devices. A review of cervico-vaginal smears in 350 women. Med J Malaysia 1994; 49: 74–77.
134. Pisharodi LR, Jovanoska S. Spectrum of cytologic changes in pregnancy. A review of 100 abnormal cervicovaginal smears, with emphasis on diagnostic pitfalls. Acta Cytol 1995; 39: 905–908.
135. Schneider V, Barnes LA. Ectopic decidual reaction of the uterine cervix: frequency and cytologic presentation. Acta Cytol 1981; 25: 616–622.
136. Michael CW, Esfahani FM. Pregnancy-related changes: a retrospective review of 278 cervical smears. Diagn Cytopathol 1997; 17: 99–107.
137. Young NA, Bibbo M, Buckner SB, Colgan TJ, Prey MU. Non-neoplastic findings. In: Solomon D, Nayar R, eds. The Bethesda System for Reporting Cervical Cytology, 2nd edn. New York, NY: Springer; 2004.
138. Fitzhugh VA, Heller DS. Significance of a diagnosis of microorganisms on pap smear. J Low Genit Tract Dis 2008; 12: 40–51.
139. Aslan DL, McKeon DM, Stelow EB, et al. The diagnosis of trichomonas vaginalis in liquid-based Pap tests: morphological characteristics. Diagn Cytopathol 2005; 32: 253–259.
140. Noel JC, Engohan-Aloghe C. Morphologic criteria associated with Trichomonas vaginalis in liquid-based cytology. Acta Cytol 2010; 54: 582–586.
141. Cibas ES. Cytology: Diagnostic Principles and Clinical Correlates. New York, NY: Saunders; 2003.
142. Takei H, Ruiz B, Hicks J. Cervicovaginal flora. Comparison of conventional pap smears and a liquid-based thin-layer preparation. Am J Clin Pathol 2006; 125: 855–859.
143. Miguel NL Jr, Lachowicz CM, Kline TS. Candida-related changes and ASCUS: a potential trap! Diagn Cytopathol 1997; 16: 83–86.
144. Larsen B, Monif GR. Understanding the bacterial flora of the female genital tract. Clin Infect Dis 2001; 32: e69–77.
145. Tokyol C, Aktepe OC, Cevrioglu AS, Altindis M, Dilek FH. Bacterial vaginosis: comparison of Pap smear and microbiological test results. Mod Pathol 2004; 17: 857–860.
146. Egan ME, Lipsky MS. Diagnosis of vaginitis. Am Fam Phys 2000; 62: 1095–1104.
147. Giacomini G, Calcinai A, Moretti D, Cristofani R. Accuracy of cervical/vaginal cytology in the diagnosis of bacterial vaginosis. Sex Transm Dis 1998; 25: 24–27.
148. Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception 2007; 75: S48–50.
149. Ratnam S, Severini A, Zahariadis G, Petric M, Romanowski B. The diagnosis of genital herpes – beyond culture: an evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology. Can J Infect Dis Med Microbiol 2007; 18: 233–240.
150. Henry MR. Chlamydia trachomatis and Female Genital Tact Infection: The Role of Cytology in Diagnosis and Treatment. Cytopathology Annual. Chicago, IL: ASCP Press; 1994.
151. Shiina Y. Cytomorphologic and immunocytochemical studies of chlamydial infections in cervical smears. Acta Cytol 1985; 29: 683–691.
152. Henry MR, de Mesy Jensen KL, Skoglund CD, Armstrong DW III. Chlamydia trachomatis in routine cervical smears. A microscopic and ultrastructural analysis. Acta Cytol 1993; 37: 343–352.
153. Watson EJ, Templeton A, Russell I, et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002; 51: 1021–1031.
154. Hunt JL, Baloch Z, Judkins A, et al. Unique cytomegalovirus intracytoplasmic inclusions in ectocervical cells on a cervical/endocervical smear. Diagn Cytopathol 1998; 18: 110–112.
155. Sekhon HS, Press RD, Schmidt WA, Hawley M, Rader A. Identification of cytomegalovirus in a liquid-based gynecologic sample using morphology, immunohistochemistry, and DNA real-time PCR detection. Diagn Cytopathol 2004; 30: 411–417.
156. Wong JY, Becker SN. Enterobius vermicularis ova in routine cervicovaginal smears. Light and scanning electron microscopic observations. Acta Cytol 1982; 26: 484–487.
157. Kjetland EF, Ndhlovu PD, Mduluza T, et al. Simple clinical manifestations of genital Schistosoma haematobium infection in rural Zimbabwean women. Am J Trop Med Hyg 2005; 72: 311–319.
158. Evans S, Dowling K. The changing prevalence of cervical human papilloma virus infection. Aust NZ J Obstet Gynaecol 1990; 30: 375–377.
159. Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000;154: 127–134.
160. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999; 103: 539–545.
161. Chan PK, Chang AR, Cheung JL, et al. Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. J Infect Dis 2002; 185: 28–35.
162. Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991–1995. Obstet Gynecol 1998; 92: 745–752.
163. Tortolero-Luna G, Mitchell MF, Swan DC, et al. A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups. Cad Saude Publica 1998;14(Suppl 3): 149–159.
164. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–265.
165. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94: 1406–1414.
166. Acladious NN, Sutton C, Mandal D, et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002; 98: 435–439.
167. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105–1112.
168. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359: 1093–1101.
169. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085–1092.
170. Petry KU, Bohmer G, Iftner T, et al. Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol 2002; 186: 28–34.
171. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283: 1031–1037.
172. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604–1613.
173. Franco EL. Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin North Am 1996; 23: 597–623.
174. Richart RM, Masood S, Syrjanen KJ, et al. Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 1998; 42: 50–58.
175. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000; 19: 16–28.
176. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958–964.
177. Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest 2002; 20: 1080–1085.
178. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796–802.
179. Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012; 50: 1867–1873.
180. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 3106–3114.
181. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20: 287–296.
182. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347–356.
183. Vousden KH. Regulation of the cell cycle by viral oncoproteins. Semin Cancer Biol 1995; 6: 109–116.
184. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS. Angiogenesis, cell proliferation and apoptosis in progression of cervical neoplasia. Anal Quant Cytol Histol 2002; 24: 103–113.
185. Thomison J III, Thomas LK, Shroyer KR. Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol 2008; 39: 154–166.
186. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994; 48: 427–447.
187. Turek LP, Smith EM. The genetic program of genital human papillomaviruses in infection and cancer. Obstet Gynecol Clin North Am 1996; 23: 735–758.
188. Kessis TD, Slebos RJ, Nelson WG, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993; 90: 3988–3992.
189. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010; 134: 193–199.
190. Clad A, Reuschenbach M, Weinschenk J, et al. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol 2011; 49: 1071–1076.
191.Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000; 92: 397–402.
192. Davey DD, Zarbo RJ. Human papillomavirus testing – are you ready for a new era in cervical cancer screening? Arch Pathol Lab Med 2003; 127: 927–929.
193. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012; 16: 175–204.
194. Reagan JW, Haminic MJ. Dysplasia of the uterine cervix. Ann NY Acad Sci 1956; 63: 662–682.
195. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973; 8: 301–328.
196. Cocker J, Fox H, Langley FA. Consistency in the histological diagnosis of epithelial abnormalities of the cervix uteri. J Clin Pathol 1968; 21: 67–70.
197. McCredie MR, Paul C, Sharples KJ, et al. Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3. Aust NZ J Obstet Gynaecol 2010;50: 363–370.
198. Kalantari M, Karlsen F, Johansson B, et al. Human papillomavirus findings in relation to cervical intraepithelial neoplasia grade: a study on 476 Stockholm women, using PCR for detection and typing of HPV. Hum Pathol 1997; 28: 899–904.
199. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 228–229.
200. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women’s Health Study. J Infect Dis 2002; 186: 462–469.
201. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79: 328–337.
202. Saito J, Fukuda T, Hoshiai H, Noda K. High-risk types of human papillomavirus associated with the progression of cervical dysplasia to carcinoma. J Obstet Gynaecol Res 1999; 25: 281–286.
203. van der Graaf Y, Molijn A, Doornewaard H, et al. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 2002; 156: 158–164.
204. Crum CP. Symposium part 1: should the Bethesda System terminology be used in diagnostic surgical pathology? Point. Int J Gynecol Pathol 2003; 22: 5–12.
205. Schneider V. Symposium part 2: should the Bethesda System terminology be used in diagnostic surgical pathology? Counterpoint. Int J Gynecol Pathol 2003; 22: 13–17.
206. Abdul-Karim FW, Fu YS, Reagan JW, Wentz WB. Morphometric study of intraepithelial neoplasia of the uterine cervix. Obstet Gynecol 1982; 60: 210–214.
207. Saito K, Saito A, Fu YS, et al. Topographic study of cervical condyloma and intraepithelial neoplasia. Cancer 1987; 59: 2064–2070.
208. Gupta JW, Saito K, Saito A, Fu YS, Shah KV. Human papillomaviruses and the pathogenesis of cervical neoplasia. A study by in situ hybridization. Cancer 1989; 64: 2104–2110.
209. Bekkers RL, Melchers WJ, Bulten J, et al. Localized distribution of human papillomavirus genotypes in the uterine cervix. Eur J Gynaecol Oncol 2002; 23: 203–206.
210. Park TW, Richart RM, Sun XW, Wright TC Jr. Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. J Natl Cancer Inst 1996; 88: 355–358.
211. Vecchione A, Zanesi N, Trombetta G, et al. Cervical dysplasia, ploidy, and human papillomavirus status correlate with loss of Fhit expression. Clin Cancer Res 2001; 7: 1306–1312.
212. Chung TK, Cheung TH, Lo WK, et al. Loss of heterozygosity at the short arm of chromosome 3 in microdissected cervical intraepithelial neoplasia. Cancer Lett 2000; 154: 189–194.
213. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186–192.
214. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252–258.
215. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425–434.
216. Richart RM, Nuovo GJ. Human papillomavirus DNA in situ hybridization may be used for the quality control of genital tract biopsies. Obstet Gynecol 1990; 75: 223–226.
217. Roteli-Martins CM, Alves VA, Santos RT, et al. Value of morphological criteria in diagnosing cervical HPV lesions confirmed by in situ hybridization and hybrid capture assay. Pathol Res Pract 2001; 197: 677–682.
218. Ziol M, Di Tomaso C, Biaggi A, et al. Virological and biological characteristics of cervical intraepithelial neoplasia grade I with marked koilocytotic atypia. Hum Pathol 1998; 29: 1068–1073.
219. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500–1505.
220. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127: 805–815.
221. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441–446.
222. Crum CP, Egawa K, Fu YS, et al. Atypical immature metaplasia (AIM). A subset of human papilloma virus infection of the cervix. Cancer 1983; 51: 2214–2219.
223. Ward BE, Saleh AM, Williams JV, Zitz JC, Crum C.P. Papillary immature metaplasia of the cervix: a distinct subset of exophytic cervical condyloma associated with HPV-6/11 nucleic acids. Mod Pathol 1992; 5: 391–395.
224. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010; 34: 1077–1087.
225. Benevolo M, Terrenato I, Mottolese M, et al. Comparative evaluation of nm23 and p16 expression as biomarkers of high-risk human papillomavirus infection and cervical intraepithelial neoplasia 2(+) lesions of the uterine cervix. Histopathology 2010; 57: 580–586.
226. Riethdorf S, Neffen EF, Cviko A, et al. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol 2004; 35: 1477–1483.
227. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006; 19: 384–391.
228. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276–284.
229. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004; 35: 689–696.
230. Dijkstra MG, Heideman DA, de Roy SC, et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010; 63: 972–977.
231. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395–406.
232. Horn LC, Reichert A, Oster A, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2008; 32: 502–512.
233. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1389–1399.
234. Ordi J, Garcia S, del Pino M, et al. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol 2009; 28: 90–97.
235. Heatley MK. What is the value of proliferation markers in the normal and neoplastic cervix? Histol Histopathol 1998; 13: 249–254.
236. Pirog EC, Isacson C, Szabolcs MJ, et al. Proliferative activity of benign and neoplastic endocervical epithelium and correlation with HPV DNA detection. Int J Gynecol Pathol 2002; 21: 22–26.
237. Mittal K. Utility of MIB-1 in evaluating cauterized cervical cone biopsy margins. Int J Gynecol Pathol 1999; 18: 211–214.
238. van Hoeven KH, Ramondetta L, Kovatich AJ, Bibbo M, Dunton CJ. Quantitative image analysis of MIB-1 reactivity in inflammatory, hyperplastic, and neoplastic endocervical lesions. Int J Gynecol Pathol 1997; 16: 15–21.
239. Pirog EC, Baergen RN, Soslow RA, et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol 2002; 26: 70–75.
240. Kruse AJ, Baak JP, Helliesen T, et al. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1501–1507.
241. Guo M, Baruch AC, Silva EG, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol 2011; 135: 212–220.
242. Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol 2010; 29: 79–87.
243. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000; 9: 542–544.
244. Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150: 300–308.
245. Halpert R, Fruchter RG, Sedlis A, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986; 68 251–258.
246. Sasadeusz J, Kelly H, Szer J, et al. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transpl 2001; 28: 393–397.
247. Volkow P, Rubi S, Lizano M, et al. High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus. Gynecol Oncol 2001; 82: 27–31.
248. Delmas MC, Larsen C, van Benthem B, et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women. Aids 2000; 14: 1775–1784.
249. Massad LS, Ahdieh L, Benning L, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2001; 27: 432–442.
250. Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16: 61–65.
251. Group, U. S. C. S. W. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013.
252. Hu X, Pang T, Asplund A, Ponten J, Nister M. Clonality analysis of synchronous lesions of cervical carcinoma based on X chromosome inactivation polymorphism, human papillomavirus type 16 genome mutations, and loss of heterozygosity. J Exp Med 2002; 195: 845–854.
253. Herbsleb M, Knudsen UB, Orntoft TF, et al. Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. Apmis 2001; 109: 607–617.
254. Bar JK, Harlozinska A, Sedlaczek P, Kasiak J, Markowska J. Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias. Anticancer Res 2001; 21: 1001–1006.
255. Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res 1998; 18: 3991–3998.
256. Prokopakis P, Sourvinos G, Koumantaki Y, Koumantakis E, Spandidos DA. K-ras mutations and HPV infection in cervicitis and intraepithelial neoplasias of the cervix. Oncol Rep 2002; 9: 129–133.
257. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19.
258. Ikenberg H, Teufel G, Schmitt B, et al. Human papillomavirus DNA in distant metastases of cervical cancer. Gynecol Oncol 1993; 48: 56–60.
259. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr 1996; 17–25.
260. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103–104.
261. Kalof K, Dadmanesh F, Longacre TA, et al. Protocol for the examination of specimens from patients with carcinoma of the uterine cervix. 2011.
262. Sevin B. Carcinoma of the cervix uteri. In: Jones HI, Burke T, Creasman W, et al., eds., SGO Handbook: Staging of Gynecologic Malignancies. Chicago, IL: Society of Gynecologic Oncologists; 1994: pp. 15–22.
263. Sevin B. Carcinoma of the cervix uteri. In: Jones HI, Burke T, Creasman W, et al., eds., SGO Handbook: Staging of Gynecologic Malignancies. Chicago, IL: Society of Gynecologic Oncologists; 1997: pp. 15–20.
264. Burghardt E, Girardi F, Lahousen M, Pickel H, Tamussino K. Microinvasive carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics Stage IA). Cancer 1991; 67: 1037–1045.
265. Takeshima N, Yanoh K, Tabata T, et al. Assessment of the revised International Federation of Gynecology and obstetrics staging for early invasive squamous cervical cancer. Gynecol Oncol 1999; 74: 165–169.
266. Benedet JL, Anderson GH. Stage IA carcinoma of the cervix revisited. Obstet Gynecol 1996; 87: 1052–1059.
267. Maiman MA, Fruchter RG, DiMaio TM, Boyce JG. Superficially invasive squamous cell carcinoma of the cervix. Obstet Gynecol 1988; 72: 399–403.
268. Lee SW, Kim YM, Son WS, et al. The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma. Acta Obstet Gynecol Scand 2009; 88: 209–215.
269. Yamaguchi H, Ueda M, Kanemura M, et al. Clinical efficacy of conservative laser therapy for early-stage cervical cancer. Int J Gynecol Cancer 2007; 17: 455–459.
270. Elliott P, Coppleson M, Russell P, et al. Early invasive (FIGO stage IA) carcinoma of the cervix: a clinico-pathologic study of 476 cases. Int J Gynecol Cancer 2000; 10: 42–52.
271. Ostor AG, Rome RM. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up. Int J Gynecol Cancer 1994; 4: 257–264.
272. Costa S, Marra E, Martinelli GN, et al. Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up. Int J Gynecol Cancer 2009; 19: 33–38.
273. Howe DT, Vincenti AC. Is large loop excision of the transformation zone (LLETZ) more accurate than colposcopically directed punch biopsy in the diagnosis of cervical intraepithelial neoplasia? Br J Obstet Gynaecol 1991; 98: 588–591.
274. Luesley DM, Cullimore J, Redman CW, et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. BMJ 1990; 300: 1690–1693.
275. Murdoch JB, Grimshaw RN, Morgan PR, Monaghan JM. The impact of loop diathermy on management of early invasive cervical cancer. Int J Gynecol Cancer 1992; 2: 129–133.
276. Tidbury P, Singer A, Jenkins D. CIN 3: the role of lesion size in invasion. Br J Obstet Gynaecol 1992; 99: 583–586.
277. Killackey MA, Jones WB, Lewis JL Jr. Diagnostic conization of the cervix: review of 460 consecutive cases. Obstet Gynecol 1986; 67: 766–770.
278. Mobius G. Cytological early detection of cervical carcinoma: possibilities and limitations. Analysis of failures. J Cancer Res Clin Oncol 1993; 119: 513–521.
279. Andersen ES, Nielsen K, Pedersen B. The reliability of preconization diagnostic evaluation in patients with cervical intraepithelial neoplasia and microinvasive carcinoma. Gynecol Oncol 1995; 59: 143–147.
280. Creasman WT, Fetter BF, Clarke-Pearson DL, Kaufmann L, Parker RT. Management of stage IA carcinoma of the cervix. Am J Obstet Gynecol 1985; 153: 164–172.
281. Simon NL, Gore H, Shingleton HM, et al. Study of superficially invasive carcinoma of the cervix. Obstet Gynecol 1986; 68: 19–24.
282. Fu YS, Berek JS. Minimal cervical cancer: definition and histology. Recent Results Cancer Res 1988; 106: 47–56.
283. Roche WD, Norris HJ. Microinvasive carcinoma of the cervix. The significance of lymphatic invasion and confluent patterns of stromal growth. Cancer 1975; 36: 180–186.
284. Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol 1989; 33: 265–272.
285. Robboy SJ, Anderson M, Russell P, eds. Pathology of the Female Reproductive Tract. London: Churchill Livingstone; 2002.
286. Ostor AG. Studies on 200 cases of early squamous cell carcinoma of the cervix. Int J Gynecol Pathol 1993; 12: 193–207.
287. Buckley SL, Tritz DM, Van Le L, et al. Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynecol Oncol 1996; 63: 4–9.
288. Delgado G, Bundy BN, Fowler WC Jr, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1989; 35: 314–320.
289. Sedlis A, Sall S, Tsukada Y, et al. Microinvasive carcinoma of the uterine cervix: a clinical–pathologic study. Am J Obstet Gynecol 1979; 133: 64–74.
290. Pretorius R, Semrad N, Watring W, Fotheringham N. Presentation of cervical cancer. Gynecol Oncol 1991; 42: 48–53.
291. Reagan JW, Hamonic MJ, Wentz WB. Analytical study of cells in cervical squamous cancer. Lab Invest 1957; 6: 241–250.
292. Wentz WB, Reagan JW. Survival in cervical cancer with respect to cell type. Cancer 1959; 12: 384–388.
293. Robert ME, Fu YS. Squamous cell carcinoma of the uterine cervix – a review with emphasis on prognostic factors and unusual variants. Semin Diagn Pathol 1990; 7: 173–189.
294. Zaino RJ, Ward S, Delgado G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer 1992; 69: 1750–1758.
295. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998; 110: 385–390.
296. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001; 116: 823–830.
297. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecol Oncol Int J Gynaecol Obstet 2000; 70: 209–262.
298. Roman LD, Felix JC, Muderspach LI, et al. Influence of quantity of lymph–vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. Gynecol Oncol 1998; 68: 220–225.
299. Comerci G, Bolger BS, Flannelly G, et al. Prognostic factors in surgically treated stage IB–IIB carcinoma of the cervix with negative lymph nodes. Int J Gynecol Cancer 1998; 8: 23–26.
300. Kristensen GB, Abeler VM, Risberg B, Trop C, Bryne M. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 1999; 74: 245–251.
301. Takeda N, Sakuragi N, Takeda M, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002; 81: 1144–1151.
302. Pickel H, Haas J, Lahousen M. Prognostic factors in cervical cancer. Eur J Obstet Gynecol Reprod Biol 1997; 71: 209–213.
303. Kamura T, Shigematsu T, Kaku T, et al. Histopathological factors influencing pelvic lymph node metastases in two or more sites in patients with cervical carcinoma undergoing radical hysterectomy. Acta Obstet Gynecol Scand 1999; 78: 452–457.
304. Stanhope CR, Smith JP, Wharton JT, et al. Carcinoma of the cervix: the effect of age on survival. Gynecol Oncol 1980; 10: 188–193.
305. Rutledge FN, Mitchell MF, Munsell M, et al. Youth as a prognostic factor in carcinoma of the cervix: a matched analysis. Gynecol Oncol 1992; 44: 123–130.
306. Bichel P, Jakobsen A, Nielsen K, Holund B, Visfeldt J. Prediction of lymph node metastases in patients with early squamous cell carcinoma of the cervix uteri by histopathological grading and flow cytometry. Eur J Cancer 1993; 29A: 337–340.
307. Huang LW, Chou YY, Chao SL, Chen TJ, Lee T. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001; 83: 348–354.
308. Soh LT, Heng D, Lee IW, et al. The relevance of oncogenes as prognostic markers in cervical cancer. Int J Gynecol Cancer 2002; 12: 465–474.
309. Kim YB, Kim GE, Cho NH, et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002; 95: 531–539.
310. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002; 87: 84–89.
311. Kedzia W, Schmidt M, Frankowski A, Spaczynski M. Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochem Cytobiol 2002; 40: 37–41.
312. Lombard I, Vincent-Salomon A, Validire P, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 1998; 16: 2613–2619.
313. Frega A, Lukic A, Nobili F, et al. Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up. Anticancer Res 2007; 27: 4491–4494.
314. Benedet JL, Clement PB. Verrucous carcinoma of the cervix and endometrium. Diagn Gynecol Obstet 1980; 2: 197–203.
315. Tiltman AJ, Atad J. Verrucous carcinoma of the cervix with endometrial involvement. Int J Gynecol Pathol 1982; 1: 221–226.
316. Cho NH, Joo HJ, Ahn HJ, Jung WH, Lee KG. Detection of human papillomavirus in warty carcinoma of the uterine cervix: comparison of immunohistochemistry, in situ hybridization and in situ polymerase chain reaction methods. Pathol Res Pract 1998; 194: 713–720.
317. Morrison C, Catania F, Wakely P Jr, Nuovo GJ. Highly differentiated keratinizing squamous cell cancer of the cervix: a rare, locally aggressive tumor not associated with human papillomavirus or squamous intraepithelial lesions. Am J Surg Pathol 2001; 25: 1310–1315.
318. Randall ME, Andersen WA, Mills SE, Kim JA. Papillary squamous cell carcinoma of the uterine cervix: a clinicopathologic study of nine cases. Int J Gynecol Pathol 1986; 5: 1–10.
319. Koenig C, Turnicky RP, Kankam CF, Tavassoli FA. Papillary squamotransitional cell carcinoma of the cervix: a report of 32 cases. Am J Surg Pathol 1997; 21: 915–921.
320. Robinson CE, Sarode VR, Albores-Saavedra J. Mixed papillary transitional cell carcinoma and adenocarcinoma of the uterine cervix: a clinicopathologic study of three cases. Int J Gynecol Pathol 2003; 22: 220–225.
321. Brinck U, Jakob C, Bau O, Fuzesi L. Papillary squamous cell carcinoma of the uterine cervix: report of three cases and a review of its classification. Int J Gynecol Pathol 2000; 19: 231–235.
322. Ortega-Gonzalez P, Chanona-Vilchis J, Dominguez-Malagon H. Transitional cell carcinoma of the uterine cervix. A report of six cases with clinical, histologic and cytologic findings. Acta Cytol 2002; 46: 585–590.
323. Albores-Saavedra J, Young RH. Transitional cell neoplasms (carcinomas and inverted papillomas) of the uterine cervix. A report of five cases. Am J Surg Pathol 1995; 19: 1138–45.
324. Steeper TA, Piscioli F, Rosai J. Squamous cell carcinoma with sarcoma-like stroma of the female genital tract. Clinicopathologic study of four cases. Cancer 1983; 52: 890–898.
325. Tseng CJ, Pao CC, Tseng LH, et al. Lymphoepithelioma-like carcinoma of the uterine cervix: association with Epstein–Barr virus and human papillomavirus. Cancer 1997; 80: 91–97.
326. Hering B, Horn LC, Nenning H, Kuhndel K. Predictive value of DNA cytometry in CIN 1 and 2. Image analysis of 193 cases. Anal Quant Cytol Histol 2000; 22: 333–337.
327. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000; 95: 821–827.
328. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999; 80: 1306–3111.
329. Evans MF, Adamson CS, Papillo JL, et al. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006; 106: 1054–1064.
330. Castle PE, Fetterman B, Thomas Cox J, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010; 116: 76–84.
331. Henry MR. Squamous epithelial abnormalities. In: College of American Pathologists Practical Guide to Gynecologic Cytopathology Morphology, Management and Molecular Methods. Chicago, IL: CAP Press; 2008.
332. Henry M, Clayton AC, Cobb CJ. Look-alikes and morphologic spectrum of changes. In: College of American Pathologists Practical Guide to Gynecologic Cytopathology Morphology, Management and Molecular Methods. Chicago, IL: CAP Press; 2008.
333. Ince U, Aydin O, Peker O. Clinical importance of “low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion (LSIL-H)” terminology for cervical smears 5-year analysis of the positive predictive value of LSIL-H compared with ASC-H, LSIL, and HSIL in the detection of high-grade cervical lesions with a review of the literature. Gynecol Oncol 2011; 121: 152–156.
334. Woodhouse SL, Stastny JF, Styer PE, et al. Interobserver variability in subclassification of squamous intraepithelial lesions: results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 1999; 123: 1079–1084.
335. Demay RM. Hyperchromatic crowded groups: pitfalls in Pap smear diagnosis. Am J Clin Pathol 2000; 114(Suppl): S36–43.
336. Frable WJ. Litigation cells: definition and observations on a cell type in cervical vaginal smears not addressed by the Bethesda System. Diagn Cytopathol 1994; 11: 213–215.
337. Hatem F, Wilbur DC. High grade squamous cervical lesions following negative Papanicolaou smears: false-negative cervical cytology or rapid progression. Diagn Cytopathol 1995; 12: 135–141.
338. Wilbur DC, Dubeshter B, Angel C, Atkison KM. Use of thin-layer preparations for gynecologic smears with emphasis on the cytomorphology of high-grade intraepithelial lesions and carcinomas. Diagn Cytopathol 1996; 14: 201–211.
339. Sherman M, Abdul-Karim FW, Berek JS, et al. Atypical squamous cells. In: Solomon D, Nayar R, eds. The Bethesda System for Reporting Cervical Cytology. New York, NY: Springer; 2004.
340. Kurman RJ, Malkasian GD Jr, Sedlis A, Solomon D. From Papanicolaou to Bethesda: the rationale for a new cervical cytologic classification. Obstet Gynecol 1991; 77: 779–782.
341. Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ. Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Phys 2009; 80: 147–155.
342. Apgar BS, Brotzman G. Management of cervical cytologic abnormalities. Am Fam Phys 2004; 70: 1905–1916.
343. Taylor RR, Guerrieri JP, Nash JD, Henry MR, O’Connor DM. Atypical cervical cytology. Colposcopic follow-up using the Bethesda System. J Reprod Med 1993; 38: 443–447.
344. Cibas ES, Zou KH, Crum CP, Kuo F. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol 2008; 129: 97–101.
345. Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis 2010; 14: 206–214.
346. Sherman ME, Kelly D. High-grade squamous intraepithelial lesions and invasive carcinoma following the report of three negative Papanicolaou smears: screening failures or rapid progression? Mod Pathol 1992; 5: 337–342.
347. Belinson JL, Pan QJ, Biscotti C, et al. Primary screening with liquid-based cytology in an unscreened population in rural China, with an emphasis on reprocessing unsatisfactory samples. Acta Cytol 2002; 46: 470–474.
348. Friedell GH, McKay DG. Adenocarcinoma in situ of endocervix. Cancer 1953; 6: 887–897.
349. Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 1986; 124: 1045–1047.
350. Lee KR, Flynn CE. Early invasive adenocarcinoma of the cervix. Cancer 2000; 89: 1048–1055.
351. Tase T, Okagaki T, Clark BA, et al. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989; 8: 8–17.
352. Boon ME, Baak JP, Kurver PJ, Overdiep SH, Verdonk GW. Adenocarcinoma in situ of the cervix: an underdiagnosed lesion. Cancer 1981; 48: 768–773.
353. Kashimura M, Shinohara M, Oikawa K, Hamasaki K, Sato H. An adenocarcinoma in situ of the uterine cervix that developed into invasive adenocarcinoma after 5 years. Gynecol Oncol 1990; 36: 128–133.
354. Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999; 75: 55–61.
355. Denehy TR, Gregori CA, Breen JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997; 90: 1–6.
356. Bertrand M, Lickrish GM, Colgan TJ. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol 1987; 157: 21–25.
357. Jaworski RC, Pacey NF, Greenberg ML, Osborn RA. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri. Adenocarcinoma in situ. Cancer 1988; 61: 1171–1181.
358. Brown LJ, Wells M. Cervical glandular atypia associated with squamous intraepithelial neoplasia: a premalignant lesion? J Clin Pathol 1986; 39: 22–28.
359. Biscotti CV, Hart WR. Apoptotic bodies: a consistent morphologic feature of endocervical adenocarcinoma in situ. Am J Surg Pathol 1998; 22: 434–439.
360. Ioffe OB, Sagae S, Moritani S, et al. Proposal of a new scoring scheme for the diagnosis of noninvasive endocervical glandular lesions. Am J Surg Pathol 2003; 27: 452–460.
361. McCluggage WG, Shah R, Connolly LE, McBride HA. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol 2008; 27: 92–100.
362. Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2002; 21: 314–326.
363. Hopkins MP. Adenocarcinoma in situ of the cervix – the margins must be clear. Gynecol Oncol 2000; 79: 4–5.
364. Goldstein NS, Mani A. The status and distance of cone biopsy margins as a predictor of excision adequacy for endocervical adenocarcinoma in situ. Am J Clin Pathol 1998; 109: 727–732.
365. Im DD, Duska LR, Rosenshein NB. Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Gynecol Oncol 1995; 59: 179–182.
366. Ostor AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol 2000; 79: 207–210.
367. Jaworski RC. Endocervical glandular dysplasia, adenocarcinoma in situ, and early invasive (microinvasive) adenocarcinoma of the uterine cervix. Semin Diagn Pathol 1990; 7: 190–204.
368. Anciaux D, Lawrence WD, Gregoire L. Glandular lesions of the uterine cervix: prognostic implications of human papillomavirus status. Int J Gynecol Pathol 1997; 16: 103–110.
369. Bousfield L, Pacey F, Young Q, Krumins I, Osborn R. Expanded cytologic criteria for the diagnosis of adenocarcinoma in situ of the cervix and related lesions. Acta Cytol 1980; 24: 283–296.
370. Higgins GD, Phillips GE, Smith LA, Uzelin DM, Burrell CJ. High prevalence of human papillomavirus transcripts in all grades of cervical intraepithelial glandular neoplasia. Cancer 1992; 70: 136–146.
371. Leary J, Jaworski R, Houghton R. In-situ hybridization using biotinylated DNA probes to human papillomavirus in adenocarcinoma-in-situ and endocervical glandular dysplasia of the uterine cervix. Pathology 1991; 23: 85–89.
372. Qizilbash AH. In-situ and microinvasive adenocarcinoma of the uterine cervix. A clinical, cytologic and histologic study of 14 cases. Am J Clin Pathol 1975; 64: 155–170.
373. Nielsen AL. Human papillomavirus type 16/18 in uterine cervical adenocarcinoma in situ and adenocarcinoma. A study by in situ hybridization with biotinylated DNA probes. Cancer 1990; 65: 2588–2593.
374. Lee KR, Sun D, Crum CP. Endocervical intraepithelial glandular atypia (dysplasia): a histopathologic, human papillomavirus, and MIB-1 analysis of 25 cases. Hum Pathol 2000; 31: 656–664.
375. Lee KR, Sun D, Crum CP. Endocervical intraepithelial glandular atypia (dysplasia): a histopathologic, human papillomavirus, and MIB-1 analysis of 25 cases. Hum Pathol 2000; 31: 656–664.
376. Zaino RJ. Glandular lesions of the uterine cervix. Mod Pathol 2000; 13: 261–274.
377. Hurlimann J, Gloor E. Adenocarcinoma in situ and invasive adenocarcinoma of the uterine cervix. An immunohistologic study with antibodies specific for several epithelial markers. Cancer 1984; 54: 103–109.
378. Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002; 33: 899–904.
379. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003; 27: 187–193.
380. Lu X, Shiozawa T, Nakayama K, et al. Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. Int J Gynecol Pathol 1999; 18: 109–114.
381. Liang J, Mittal KR, Wei JJ, et al. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol 2007; 26: 71–75.
382. Fu YS, Berek JS, Hilborne LH. Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Appl Pathol 1987; 5: 47–56.
383. Ostor A, Rome R, Quinn M. Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. Obstet Gynecol 1997; 89: 88–93.
384. Ostor AG. Early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2000; 19: 29–38.
385. Wheeler DT, Kurman RJ. The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol 2005; 24: 125–130.
386. Teshima S, Shimosato Y, Kishi K, et al. Early stage adenocarcinoma of the uterine cervix. Histopathologic analysis with consideration of histogenesis. Cancer 1985; 56: 167–172.
387. Berek JS, Hacker NF, Fu YS, et al. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 1985; 65: 46–52.
388. Kaku T, Kamura T, Sakai K, et al. Early adenocarcinoma of the uterine cervix. Gynecol Oncol 1997; 65: 281–285.
389. Yahata T, Nishino K, Kashima K, et al. Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term follow-up. Int J Gynecol Cancer 2010; 20: 1063–1066.
390. Spoozak L, Lewin SN, Burke WM, et al. Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 2012; 206: 80.e1–6.
391. Adegoke O, Kulasingam S, Virnig, B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Hlth (Larchmt) 2012; 21: 1031–1037.
392. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol 2000; 78: 97–105.
393. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000; 89: 1291–1299.
394. Patnick J. Cervical cancer screening in England. Eur J Cancer 2000; 36: 2205–2208.
395. Popadiuk C, Stankiewicz A, Dickinson J, et al. Invasive cervical cancer incidence and mortality among Canadian women aged 15 to 29 and the impact of screening. J Obstet Gynaecol Can 2012; 34: 1167–1176.
396. Brinton LA, Tashima KT, Lehman HF, et al. Epidemiology of cervical cancer by cell type. Cancer Res 1987; 47: 1706–1711.
397. Kjaer SK, Brinton LA. Adenocarcinomas of the uterine cervix: the epidemiology of an increasing problem. Epidemiol Rev 1993; 15: 486–498.
398. Cuzick J, Terry G, Ho L, et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000; 82: 1348–1352.
399. Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986; 38: 339–344.
400. Lacey JV Jr, Brinton LA, Abbas FM, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999; 8: 1079–1085.
401. Lacey JV Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000; 77: 149–154.
402. Kaminski PF, Norris HJ. Coexistence of ovarian neoplasms and endocervical adenocarcinoma. Obstet Gynecol 1984; 64: 553–556.
403. Young RH, Scully RE. Mucinous ovarian tumors associated with mucinous adenocarcinomas of the cervix. A clinicopathological analysis of 16 cases. Int J Gynecol Pathol 1988; 7: 99–111.
404. Fu YS, Reagan JW, Hsiu JG, Storaasli JP, Wentz WB. Adenocarcinoma and mixed carcinoma of the uterine cervix. I. A clinicopathologic study. Cancer 1982; 49: 2560–2570.
405. Hou J, Goldberg GL, Qualls CR, et al. Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol 2011; 121: 135–142.
406. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer 1989; 63: 1773–1779.
407. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases. Int J Gynecol Pathol 1993; 12: 1–7.
408. Kaku T, Kamura T, Shigematsu T, et al. Adenocarcinoma of the uterine cervix with predominantly villogladular papillary growth pattern. Gynecol Oncol 1997; 64: 147–152.
409. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002; 21: 11–15.
410. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002; 21: 4–10.
411. Kamoi S, AlJuboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002; 21: 217–223.
412. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. VirchowsArch 2003; 442: 271–277.
413. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002; 26: 998–1006.
414. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003; 22: 231–235.
415. Jones MW, Onisko A, Dabbs DJ, et al. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors. Int J Gynecol Cancer 2013; 23: 380–384.
416. Chen RJ, Lin YH, Chen CA, et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999; 73: 184–190.
417. Ishikawa H, Nakanishi T, Inoue T, Kuzuya K. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 1999; 73: 42–46.
418. Benda JA, Platz CE, Buchsbaum H, Lifshitz S. Mucin production in defining mixed carcinoma of the uterine cervix: a clinicopathologic study. Int J Gynecol Pathol 1985; 4: 314–327.
419. Saigo PE, Cain JM, Kim WS, et al. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986; 57: 1584–1593.
420. Covens A, Kirby J, Shaw P, Chapman W, Franseen E. Prognostic factors for relapse and pelvic lymph node metastases in early stage I adenocarcinoma of the cervix. Gynecol Oncol 1999; 74: 423–427.
421. Kaku T, Enjoji M. Extremely well-differentiated adenocarcinoma (“adenoma malignum”) of the cervix. Int J Gynecol Pathol 1983; 2: 28–41.
422. Michael H, Grawe L, Kraus FT. Minimal deviation endocervical adenocarcinoma: clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen, and differentiation from confusing benign lesions. Int J Gynecol Pathol 1984; 3: 261–276.
423. Hirai Y, Takeshima N, Haga A, et al. A clinicocytopathologic study of adenoma malignum of the uterine cervix. Gynecol Oncol 1998; 70: 219–223.
424. Fujiwaki R, Takahashi K, Kitao M. Adenoma malignum of the uterine cervix associated with Peutz–Jeghers syndrome. Int J Gynaecol Obstet 1996; 53: 171–172.
425. Kuragaki C, Enomoto T, Ueno Y, et al. Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest 2003; 83: 35–45.
426. Young RH, Scully RE. Minimal-deviation endometrioid adenocarcinoma of the uterine cervix. A report of five cases of a distinctive neoplasm that may be misinterpreted as benign. Am J Surg Pathol 1993; 17: 660–665.
427. Gilks CB, Young RH, Aguirre P, DeLellis RA, Scully RE. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol 1989; 13: 717–729.
428. Goodman HM, Buttlar CA, Niloff JM, et al. Adenocarcinoma of the uterine cervix: prognostic factors and patterns of recurrence. Gynecol Oncol 1989; 33: 241–247.
429. Young RH, Scully RE. Invasive adenocarcinoma and related tumors of the uterine cervix. Semin Diagn Pathol 1990; 7: 205–227.
430. Germain M, Heaton R, Erickson D, et al. A comparison of the three most common Papanicolaou smear collection techniques. Obstet Gynecol 1994; 84: 168–173.
431. Novotny DB, Maygarden SJ, Johnson DE, Frable WJ. Tubal metaplasia. A frequent potential pitfall in the cytologic diagnosis of endocervical glandular dysplasia on cervical smears. Acta Cytol 1992; 36: 1–10.
432. Korhonen MO. Adenocarcinoma of the uterine cervix. An evaluation of the available diagnostic methods. Acta Pathol Microbiol Scand Suppl 1978; 1–59.
433. Hurt WG, Silverberg SG, Frable WJ, Belgrad R, Crooks LD. Adenocarcinoma of the cervix: histopathologic and clinical features. Am J Obstet Gynecol 1977; 129: 3043–15.
434. Solomon D, Frable WJ, Vooijs GP, et al. ASCUS and AGUS criteria. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 1998; 42: 16–24.
435. Nguyen TN, Bourdeau JL, Ferenczy A, Franco EL. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol 1998; 19: 89–93.
436. Chang A, Sandweiss L, Bose S. Cytologically benign endometrial cells in the papanicolaou smears of postmenopausal women. Gynecol Oncol 2001; 80: 37–43.
437. de Peralta-Venturino MN, Purslow MJ, Kini, SR. Endometrial cells of the “lower uterine segment” (LUS) in cervical smears obtained by endocervical brushings: a source of potential diagnostic pitfall. Diagn Cytopathol 1995; 12: 263–268; discussion 268–271.
438. Gray JA, Nguyen GK. Cytologic detection of endometrial pathology by Pap smears. Diagn Cytopathol 1999; 20: 181–182.
439. Cherkis RC, Patten SF Jr, Andrews TJ, Dickinson JC, Patten FW. Significance of normal endometrial cells detected by cervical cytology. Obstet Gynecol 1988; 71: 242–244.
440. Yancey M, Magelssen D, Demaurez A, Lee RB. Classification of endometrial cells on cervical cytology. Obstet Gynecol 1990; 76: 1000–1005.
441. Raab SS, Snider TE, Potts SA, et al. Atypical glandular cells of undetermined significance. Diagnostic accuracy and interobserver variability using select cytologic criteria. Am J Clin Pathol 1997; 107: 299–307.
442. Lee KR, Manna EA, St John T. Atypical endocervical glandular cells: accuracy of cytologic diagnosis. Diagn Cytopathol 1995; 13: 202–208.
443. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 2000; 124: 665–671.
444. Schnatz PF, Guile M, O’Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107: 701–708.
445. Obenson K, Abreo F, Grafton WD. Cytohistologic correlation between AGUS and biopsy-detected lesions in postmenopausal women. Acta Cytol 2000; 44: 41–45.
446. Raab SS, Isacson C, Layfield LJ, et al. Atypical glandular cells of undetermined significance. Cytologic criteria to separate clinically significant from benign lesions. Am J Clin Pathol 1995;104: 574–582.
447. Betsill WL Jr, Clark AH. Early endocervical glandular neoplasia. I. Histomorphology and cytomorphology. Acta Cytol 1986; 30: 115–126.
448. Biscotti CV, Gero MA, Toddy SM, Fischler DF, Easley KA. Endocervical adenocarcinoma in situ: an analysis of cellular features. Diagn Cytopathol 1997; 17: 326–332.
449. Clayton A. Glandular epithelial abnormalities. In College of American Pathologists Practical Guide to Gynecologic Cytopathology Morphology, Management and Molecular Methods. Chicago, IL: CAP Press; 2008.
450. Lee KR. Adenocarcinoma in situ with a small cell (endometrioid) pattern in cervical smears: a test of the distinction from benign mimics using specific criteria. Cancer 1999; 87: 254–258.
451. Roberts JM, Thurloe JK, Bowditch RC, Humcevic J, Laverty CR. Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ. Acta Cytol 1999; 43: 74–80.
452. Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. ThinPrep Pap test. Accuracy for glandular disease. Acta Cytol 1999; 43: 81–85.
453. Johnson JE, Rahemtulla A. Endocervical glandular neoplasia and its mimics in ThinPrep Pap tests. A descriptive study. Acta Cytol 1999; 43: 369–375.
454. Selvaggi SM, Haefner HK. Microglandular endocervical hyperplasia and tubal metaplasia: pitfalls in the diagnosis of adenocarcinoma on cervical smears. Diagn Cytopathol 1997; 16: 168–173.
455. Lee KR. Atypical glandular cells in cervical smears from women who have undergone cone biopsy. A potential diagnostic pitfall. Acta Cytol 1993; 37: 705–709.
456. Ronnett BM, Manos MM, Ransley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999; 30: 816–825.
457. Zucker PK, Kasdon EJ, Feldstein ML. The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women. Cancer 1985; 56: 2256–2263.
458. dos Reis R, Frumovitz M, Milam MR, et al. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol 2007; 107: 458–463.
459. Pak HY, Yokota SB, Paladugu RR, Agliozzo CM. Glassy cell carcinoma of the cervix. Cytologic and clinicopathologic analysis. Cancer 1983; 52: 307–312.
460. Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer 1997; 79: 2229–2236.
461. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000; 157: 1055–1062.
462. Gilks CB, Clement PB. Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. Mod Pathol 1992; 5: 426–431.
463. Grayson W, Taylor LF, Cooper K. Adenoid cystic and adenoid basal carcinoma of the uterine cervix: comparative morphologic, mucin, and immunohistochemical profile of two rare neoplasms of putative ‘reserve cell’ origin. Am J Surg Pathol 1999; 23: 448–458.
464. Brainard JA, Hart WR. Adenoid basal epitheliomas of the uterine cervix: a reevaluation of distinctive cervical basaloid lesions currently classified as adenoid basal carcinoma and adenoid basal hyperplasia. Am J Surg Pathol 1998; 22: 965–975.
465. Ferry JA. Adenoid basal carcinoma of the uterine cervix: evolution of a distinctive clinicopathologic entity. Int J Gynecol Pathol 1997; 16: 299–300.
466. Grayson W, Taylor LF, Cooper K. Adenoid basal carcinoma of the uterine cervix: detection of integrated human papillomavirus in a rare tumor of putative “reserve cell” origin. Int J Gynecol Pathol 1997; 16: 307–312.
467. Ferry JA, Scully RE. Mesonephric remnants, hyperplasia, and neoplasia in the uterine cervix. A study of 49 cases. Am J Surg Pathol 1990; 14: 1100–1111.
468. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, Tavassoli FA. Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol 2001; 25: 379–387.
469. Clement PB, Young RH, Keh P, Ostor AG, Scully RE. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol 1995; 19: 1158–1171.
470. Kondi-Pafitis A, Kairi E, Kontogianni KI, et al. Immunopathological study of mesonephric lesions of cervix uteri and vagina. Eur J Gynaecol Oncol 2003; 24: 154–156.
471. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003; 27: 178–186.
472. Tambouret R, Bell DA, Young RH. Microcystic endocervical adenocarcinomas: a report of eight cases. Am J Surg Pathol 2000; 24: 369–374.
473. Grayson W, Taylor LF, Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol 2001; 25: 338–347.
474. Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK. Malignant mixed mullerian tumor (MMMT) of the cervix. Gynecol Oncol 2005; 97: 442–445.
475. Grayson W, Rhemtula HA, Taylor LF, Allard U, Tiltman AJ. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. J Clin Pathol 2002; 55: 108–114.
476. Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol 2003; 22: 226–230.
477. Gersell DJ, Mazoujian G, Mutch DG, Rudloff MA. Small-cell undifferentiated carcinoma of the cervix. A clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol 1988; 12: 684–698.
478. Albores-Saavedra J, Latif S, Carrick KS, Alvarado-Cabrero I, Fowler MR. CD56 reactivity in small cell carcinoma of the uterine cervix. Int J Gynecol Pathol 2005; 24: 113–117.
479. Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991; 15: 28–32.
480. Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 1991; 4: 586–593.
481. Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer 1994; 73: 672–677.
482. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 2003; 97: 568–574.
483. Wistuba II, Thomas B, Behrens C, et al. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol 1999; 72: 3–9.